Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
about
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discoveredThe role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionThe role of maintenance therapy in acute promyelocytic leukemia in first complete remissionFlow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemiaMolecules that target nucleophosmin for cancer treatment: an updateTranslating cancer genomes and transcriptomes for precision oncologyAcute promyelocytic leukemia: where did we start, where are we now, and the futureAcute Promyelocytic Leukemia (APL): Comparison Between Children and AdultsPathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndromeThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaUse of whole-genome sequencing to diagnose a cryptic fusion oncogene.Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.The origin and evolution of mutations in acute myeloid leukemiaThromboembolic and bleeding complications in acute leukemia.Acute promyelocytic leukemia presenting as an extradural mass.Differentiation therapy of leukemia: 3 decades of development.Central nervous system haemorrhage causing early death in acute promyelocytic leukaemiaGenetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Curing all patients with acute promyelocytic leukemia: are we there yet?Central nervous system involvement of acute promyelocytic leukemia, three case reports.Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Molecular Profiling: A Case of ZBTB16-RARA Acute Promyelocytic Leukemia.Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaVitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapyArsenic trioxide - An old drug rediscovered.Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Treatment advances have not improved the early death rate in acute promyelocytic leukemia.SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129.Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patientsA Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adultsArsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Therapy-related acute promyelocytic leukemia: a systematic review.Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acid-induced differentiation and apoptosis.Using functional genomics to overcome therapeutic resistance in hematological malignancies.The European LeukemiaNet: achievements and perspectives.Embryo cryopreservation in a case of acute promyelocytic leukemia, incidentally diagnosed during ovarian stimulation for in-vitro fertilization.The WNKs: atypical protein kinases with pleiotropic actions.Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells.
P2860
Q23671266-309050C1-6DF2-4102-91CB-EF180AADB16DQ24200224-48A59C45-779E-4EB1-BD3C-9A7CB03591CAQ24203970-A25E78AD-0304-4AE8-A99C-5AAA7AD15E13Q24604850-0013E897-794D-4DFB-8897-FBD7DE4E223DQ26750653-F3F6D344-3EA2-4CDA-9B7C-ACFA400F315AQ26777081-01185C68-24A7-44DE-9A7C-78D97BD36688Q26830385-0001A0E3-15FB-4421-AA61-172F7DD17F75Q27009433-B244DEE2-6392-463D-9741-E8EAFEC356C9Q27012691-65A034F0-1EA9-4A2C-96B3-6DB79DD26531Q27014790-3D9D3F0F-170A-4E26-A58F-A5489A94FAA0Q27851641-12994713-811E-412F-AFFD-06090466BE3AQ27851694-41FD8913-6BFE-4427-80AF-FA0CA8F70F4FQ29614630-849064EC-73D9-462D-A1A0-F62C3C52106FQ33392897-578CE023-389E-43A4-9D48-D6F67A94B238Q33403716-8265946B-0776-43A5-995C-A17697C60169Q33409795-285641D8-CE3A-418B-AAB0-9CF26F115F27Q33429901-97056F66-0D8A-4F7B-B9FD-297B8322542BQ33555627-ED6EDC1F-B9AD-4DD1-9426-390454E641F3Q33613426-F77A8E29-13F1-48A1-843E-78D5A6A68C10Q33625750-CF50BB51-ABE1-45C6-BEC9-34316EB28C46Q33631350-7AD335C6-BF55-4286-8C44-277B06562F56Q33654464-4BA0D1BF-59E3-479C-8459-BD2F2BD28E4AQ33710730-399CC509-E21C-4152-A6C3-D76DF57DF5C0Q33759350-2AC67F1A-46E3-4A20-B21E-F9E15F23ABA6Q34054167-2EFEEADB-AD6E-47F2-857A-56633B635358Q34144553-A9E2D5A2-4ACB-479D-9F01-ED638993D84AQ34193514-600B42BC-E118-4DE5-92FA-11DD92CC054DQ34223654-29F1AC5A-C02E-4887-873C-85F1DABF6509Q34226368-010CD606-B6F7-4818-8A3E-3554C698B15BQ34240112-73CA8AFB-0673-4241-A682-B6FC423DD8A5Q34267949-19B517C4-9DDD-4678-A775-E86F53E6DE85Q34305899-811D12AF-F013-4787-9CFD-6238406B65DEQ34310859-3DB84F59-050F-461C-B9F8-BCED66A7051AQ34351253-5CF76F09-55FD-46D2-A145-08AE9313E536Q34389148-11A9536D-CFC6-4031-B2DA-9CD8B7049983Q34401328-56EC38B6-DABF-46C7-8F8F-CB727CC7FB6EQ34451619-E01E61FC-9C89-40DB-AF26-0AE4B16D96C7Q34500338-D64693F8-19D9-4560-A8BD-A8A3BA4F5390Q34560188-AA696381-F259-43C2-A71F-8D09FE2B511AQ34608747-CC17F1DF-3B28-44DF-8B65-5C783FF7F662
P2860
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Management of acute promyelocy ...... f of the European LeukemiaNet.
@ast
Management of acute promyelocy ...... f of the European LeukemiaNet.
@en
Management of acute promyelocy ...... f of the European LeukemiaNet.
@nl
type
label
Management of acute promyelocy ...... f of the European LeukemiaNet.
@ast
Management of acute promyelocy ...... f of the European LeukemiaNet.
@en
Management of acute promyelocy ...... f of the European LeukemiaNet.
@nl
prefLabel
Management of acute promyelocy ...... f of the European LeukemiaNet.
@ast
Management of acute promyelocy ...... f of the European LeukemiaNet.
@en
Management of acute promyelocy ...... f of the European LeukemiaNet.
@nl
P2093
P50
P1433
P1476
Management of acute promyelocy ...... f of the European LeukemiaNet.
@en
P2093
Alan K Burnett
David Grimwade
Elihu H Estey
Eva Lengfelder
Miguel A Sanz
Thomas Büchner
Tomoki Naoe
P304
P356
10.1182/BLOOD-2008-04-150250
P407
P577
2008-09-23T00:00:00Z